drugset
drugset / Trial / NCT04165837

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

NCT04165837 ↗

Phase 1 Completed 24 enrolled 1ST Biotherapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.

Timeline

Start
2019-10-14
Primary completion
2021-11-12
Completion
2022-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject FB-101 Unknown — Oral

Indications

Parkinson disease